Results By optimizing the expression plasmids, recombinant VLPs of four antigenically different DENV serotypes DENV1-4 were successfully produced in 293T cells. Vaccination with virus-like particles (VLPs has shown considerable promise for many viral diseases, but the effect of DENV VLPs to induce specific immune responses has not been adequately investigated. However, there is currently no specific treatment for dengue fever, and licensed vaccine against dengue is not available. Vaccination with dengue virus-like particles induces humoral and cellular immune responses in miceĭirectory of Open Access Journals (Sweden)įull Text Available Abstract Background The incidence of dengue, an infectious disease caused by dengue virus (DENV, has dramatically increased around the world in recent decades and is becoming a severe public health threat.
